Technology
Health
Biotechnology

Concert Pharmaceuticals

$14.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.16 (-1.11%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CNCE and other stocks, options, ETFs, and crypto commission-free!

About

Concert Pharmaceuticals, Inc. Common Stock, also called Concert Pharmaceuticals, is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Read More Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Employees
71
Headquarters
Lexington, Massachusetts
Founded
2006
Market Cap
336.56M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
177.31K
High Today
$14.92
Low Today
$13.90
Open Price
$14.48
Volume
55.76K
52 Week High
$23.17
52 Week Low
$10.80

Collections

Technology
Health
Biotechnology
Top Movers
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO

News

Seeking AlphaMar 19

Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow

The following slide deck was published by Concert Pharmaceuticals, Inc. in conjunction with this event. 1 20 Click to enlarge Notes:...

94
BusinessWireMar 6

Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is intended to inform the optimal dosing regimen for CTP-543 for future clinical trials. This open label trial follows the announcement of positive results from an interim analysis of an ongoing placebo-controlled Phase 2 trial that showed significant...

131
Seeking AlphaMar 1

Concert Pharmaceuticals' (CNCE) CEO Roger Tung on Q4 2018 Results - Earnings Call Transcript

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Justine Koenigsberg – Senior Vice President, Corporate Communications and Investor Relations Roger Tung – President and Chief Executive Officer Jim Cassella – Chief Development Officer Marc Becker – Chief Financial Officer Conference Call Participants Carter Gould – UBS Alex Lim – Mizuho Adam Walsh – Stifel Operator Good morning, ladies and gentlemen, and welcome to the C...

7

Earnings

-$0.89
$1.22
$3.33
$5.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.